Enlarge / A vial containing Moderna COVID-19 booster vaccine at a vaccination center. (credit: Getty | SOPA Images)
Moderna’s updated COVID-19 vaccine provided a “significant boost” in people’s neutralizing antibody levels against the latest omicron SARS-CoV-2 subvariants circulating in the US, that is, EG.5 and FL.1.5.1, according to a press release from the company.
The updated booster shot is expected to be authorized and rolled out in the coming weeks.
Moderna, which was reporting its takeaway from preliminary clinical trial data, did not release additional details of the study, including the number of trial participants or the relative increase of neutralizing antibody levels. But the announcement aimed to ease concerns about whether the fall booster will adequately match this season’s variants.
Read 5 remaining paragraphs | Comments